Benzinga
Benzinga
Notizie dall’Italia
Azioni
Indici
Obbligazioni
ETF
Economia
Generale
Notizie USA
Azioni
Indici
Utili
Notizie Economiche
Mercati di previsione
Mercati privati
Altri Mercati
Dicono gli Analisti
Trading
Comunicati stampa
Notizie internazionali
Europa
Asia
Criptovalute
Notizie
Altcoin
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Finanza personale
Investire in criptovalute
Investire in azioni
Forex
Benzinga
martedì, ottobre 06
Notizie dall’Italia
Azioni
Indici
Obbligazioni
ETF
Economia
Generale
Notizie USA
Azioni
Indici
Utili
Notizie Economiche
Mercati di previsione
Mercati privati
Altri Mercati
Dicono gli Analisti
Trading
Comunicati stampa
Notizie internazionali
Europa
Asia
Criptovalute
Notizie
Altcoin
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Finanza personale
Investire in criptovalute
Investire in azioni
Forex
PDS Biotechnology Corp
PDSB
NASDAQ
Watchlist
Get Report
Trade with Public
Get Report
Trade with Public
$1.07
-0.13
-10.42%
Ult. Agg.: Oct 6, 12:04 PM
$1.17
-0.03
-2.5%
Get Report
Panoramica
Notizie
Previsioni utili
Eventi
Obiettivi di prezzo
Dati finanziari
Sentiment
Azionariato
Confronta
Opzioni
Rapporto azionario
Privacy Manager
PDS Biotechnology Financials
PDS Biotechnology (PDSB) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
PRO
PDS Biotechnology Q2 EPS $(0.18) Misses $(0.13) Estimate
PDS Biotechnology (NASDAQ:PDSB) reported quarterly losses of $(0.18) per share which missed the analyst consensus estimate of $(0.13) by 38.46 percent. This is a 14.29 percent increase over losses of $(0.21) per share
Benzinga Newsdesk
Earnings Scheduled For May 13, 2026
Benzinga Insights
PRO
PDS Biotechnology Q1 EPS $(0.13) Beats $(0.15) Estimate
PDS Biotechnology (NASDAQ:PDSB) reported quarterly losses of $(0.13) per share which beat the analyst consensus estimate of $(0.15) by 13.33 percent. This is a 38.1 percent increase over losses of $(0.21) per share from
Benzinga Newsdesk
PRO
PDS Biotechnology Q4 EPS $(0.14) Beats $(0.20) Estimate
PDS Biotechnology (NASDAQ:PDSB) reported quarterly losses of $(0.14) per share which beat the analyst consensus estimate of $(0.20) by 30 percent. This is a 33.33 percent increase over losses of $(0.21) per share from
Benzinga Newsdesk
Earnings Scheduled For March 30, 2026
Benzinga Insights
PRO
PDS Biotechnology Corp Reported FY25 EPS Loss Of $0.74/Share, Cash Balance Of $26.7M
Full Year 2025 Financial ResultsNet loss for the year ended December 31, 2025, was approximately $34.5 million, or $0.74 per basic and diluted share, compared to a net loss of $37.6 million, or $1.03 per basic and
Benzinga Newsdesk
